SEARCH

SEARCH BY CITATION

References

  • Ammassari A, Murri R, Pezzotti P et al. (2001) Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes 28, 445449.
  • Ammassari A, Trotta MP, Murri R et al. (2002) Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. Journal of Acquired Immune Deficiency Syndromes 31, S123S127.
  • Bassetti S, Battegay M, Furrer H et al. (1999) Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes 21, 114119.
  • Bussmann H, Wester CW, Ndwapi N et al. (2008) Five-year outcomes of initial patients treated in Botswana’s National Antiretroviral Treatment Program. AIDS 22, 23032311.
  • Carr A & Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356, 14231430.
  • Collini P, Schwab U, Sarfo S et al. (2009) Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort. Clinical Infectious Diseases 48, 988991.
  • Egger S, Petoumenos K, Kamarulzaman A et al. (2009) Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: the Asia Pacific HIV Observational Database (APHOD). Journal of Acquired Immune Deficiency Syndromes 50, 513520.
  • Etard JF, Ndiaye I, Thierry-Mieg M et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20, 11811189.
  • Fellay J, Boubaker K, Ledergerber B et al. (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358, 13221327.
  • Ferradini L, Laureillard D, Prak N et al. (2007) Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 21, 22932301.
  • Friis-Moller N, Sabin CA, Weber R et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 349, 19932003.
  • Gandhi RT, Spritzler J, Chan E et al. (2006) Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. Journal of Acquired Immune Deficiency Syndromes 42, 426434.
  • Garcia F, de Lazari E, Plana M et al. (2004) Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. Journal of Acquired Immune Deficiency Syndromes 36, 702713.
  • Harrigan PR, Hogg RS, Dong WW et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. Journal of Infectious Diseases 191, 339347.
  • Hemelaar J, Gouws E, Ghys PD & Osmanov S (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20, W13W23.
  • Homsanit M, Nelson KE, Sonjai A, Anekthananon T, Suwanagool S & Cofrancesco J Jr (2007) Body shape and metabolic abnormalities in Thai HIV-infected patients. AIDS Research and Human Retroviruses 23, 13141321.
  • Hunt PW, Deeks SG, Rodriguez B et al. (2003) Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17, 19071915.
  • Hurst M & Noble S (1999) Stavudine: an update of its use in the treatment of HIV infection. Drugs 58, 919949.
  • Justice AC, Rabeneck L, Hays RD, Wu AW & Bozzette SA (1999) Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. Journal of Acquired Immune Deficiency Syndromes 21, 126133.
  • Kelley CF, Kitchen CM, Hunt PW et al. (2009) Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clinical Infectious Diseases 48, 787794.
  • Mauss S, Corzillius M, Wolf E et al. (2002) Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Medicine 3, 4955.
  • Mills EJ, Nachega JB, Bangsberg DR et al. (2006) Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine 3, e438.
  • Mocroft A, Phillips AN, Gatell J et al. (2007) Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370, 407413.
  • Nash D, Katyal M, Brinkhof MW et al. (2008) Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 22, 22912302.
  • Orrell C, Bangsberg DR, Badri M & Wood R (2003) Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 17, 13691375.
  • Paton NI, Earnest A, Ng YM, Karim F & Aboulhab J (2002) Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clinical Infectious Diseases 35, 12441249.
  • Saint-Marc T, Partisani M, Poizot-Martin I et al. (1999) A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13, 16591667.
  • Srasuebkul P, Ungsedhapand C, Ruxrungtham K et al. (2007) Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine 8, 4654.
  • Tam LW, Chui CK, Brumme CJ et al. (2008) The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. Journal of Acquired Immune Deficiency Syndromes 49, 266271.
  • Walsh JC, Mandalia S & Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16, 269277.
  • Weiser S, Wolfe W, Bangsberg D et al. (2003) Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes 34, 281288.
  • World Health Organization (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. (2006 Revision). World Health Organization, Geneva.
  • World Health Organization (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach (2010 Revision). World Health Organization, Geneva.
  • Yamashita TE, Phair JP, Munoz A et al. (2001) Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 15, 735746.